Author Archives: Guest Blogger

UK’s Controversial Cancer Fund Boosted — But What’s the Long-Term Plan?

By Leela Barham. The English Cancer Drugs Fund (CDF), set up to provide funding for those products that the National Institute for Health and Care Excellence (NICE) has not recommended for use or where their guidance isn’t yet available, remains controversial. Initially penciled for closure in 2014, it is now planned to run to 2016. […]
Posted in Europe, Guest Blog, Op-Ed, pricing | Tagged , , , , , , | Leave a comment

Europe: More Direct-Acting Antivirals, More Controversy

The storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir). Just two months after the European Medicines Agency gave a positive opinion on the drug, the formal authorization was delivered for use in […]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing, Regulatory | Tagged , , , , , , | Leave a comment

From the Generic to the Supergeneric Era

By Adeline Siew, Pharmaceutical Technology. Generic drugs save patients and European healthcare systems approximately EUR 35 billion (US$46bn) each year, according to the European Generics Association (EGA). Of the 16 health-related recommendations made by the European Commission for 2014–2015 to EU member states, 11 concerned cost efficiency in the healthcare sector. But, speaking at the EGA […]
Posted in Europe, Events, Guest Blog, Regulatory | Tagged , , , | Leave a comment

Ebola Debates Turn Everyone into an Expert

It is a tragic truism to remark that the merits of the pharma sector are most sharply perceived only at times of deep human suffering. The debates engendered by the latest Ebola outbreak neatly if nastily demonstrate the point. All of a sudden, the mass media and social networks are reflecting wide public demands for […]
Posted in Global, Guest Blog, healthcare, Op-Ed | Tagged | Leave a comment

mHealth Set to Transform Clinical Trials

The health sciences industry received some important and encouraging news from the US Food and Drug Administration (FDA) in late June—an announcement that may, ultimately, help to transform the way data is collected in clinical trials and lead to safer studies and faster time to market. The FDA issued new draft guidance that stated its […]
Posted in R&D, Technology | Tagged , , | Leave a comment
  • Categories

  • Meta